Altimmune Inc (ALT)
8.68
+0.28
(+3.27%)
USD |
NASDAQ |
Nov 22, 16:00
8.65
-0.03
(-0.35%)
After-Hours: 20:00
Altimmune Free Cash Flow: -78.12M for Sept. 30, 2024
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2024 | -78.12M |
| June 30, 2024 | -71.48M |
| March 31, 2024 | -72.76M |
| December 31, 2023 | -75.86M |
| September 30, 2023 | -76.67M |
| June 30, 2023 | -71.29M |
| March 31, 2023 | -68.64M |
| December 31, 2022 | -62.71M |
| September 30, 2022 | -67.49M |
| June 30, 2022 | -70.27M |
| March 31, 2022 | -80.24M |
| December 31, 2021 | -90.55M |
| September 30, 2021 | -81.86M |
| June 30, 2021 | -73.55M |
| March 31, 2021 | -54.10M |
| December 31, 2020 | -34.65M |
| September 30, 2020 | -23.23M |
| June 30, 2020 | -16.08M |
| March 31, 2020 | -11.90M |
| December 31, 2019 | -9.631M |
| September 30, 2019 | -12.79M |
| June 30, 2019 | -11.54M |
| March 31, 2019 | -8.296M |
| December 31, 2018 | -10.40M |
| September 30, 2018 | -10.08M |
| Date | Value |
|---|---|
| June 30, 2018 | -13.17M |
| March 31, 2018 | -21.21M |
| December 31, 2017 | -20.38M |
| September 30, 2017 | -17.08M |
| June 30, 2017 | -14.81M |
| March 31, 2017 | -8.618M |
| December 31, 2016 | -6.574M |
| September 30, 2016 | -6.887M |
| June 30, 2016 | -6.213M |
| March 31, 2016 | -1.909M |
| December 31, 2015 | -3.302M |
| September 30, 2015 | -4.978M |
| June 30, 2015 | -5.776M |
| March 31, 2015 | -8.984M |
| December 31, 2014 | -8.566M |
| September 30, 2014 | -11.30M |
| June 30, 2014 | -9.854M |
| March 31, 2014 | -9.819M |
| December 31, 2013 | -7.253M |
| September 30, 2013 | -3.141M |
| June 30, 2013 | -0.7161M |
| March 31, 2013 | -2.879M |
| December 31, 2012 | -2.323M |
| September 30, 2012 | -0.983M |
| June 30, 2012 | -6.377M |
Free Cash Flow Range, Past 5 Years
-90.55M
Minimum
Dec 2021
-9.631M
Maximum
Dec 2019
-59.55M
Average
-70.78M
Median
Free Cash Flow Benchmarks
| Eli Lilly and Co | -2.275B |
| Viking Therapeutics Inc | -74.25M |
| Amgen Inc | 6.283B |
| Avid Bioservices Inc | -11.45M |
| NovaBay Pharmaceuticals Inc | -4.812M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -27.12M |
| Cash from Investing (Quarterly) | 1.199M |
| Cash from Financing (Quarterly) | 0.266M |
| Free Cash Flow Per Share (Quarterly) | -0.3815 |
| Free Cash Flow to Equity (Quarterly) | -27.12M |
| Free Cash Flow Yield | -13.27% |